3 news items
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
LRMR
30 May 24
strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
LRMR
20 May 24
with the FDA and overall development plan and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
development plan and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial
- Prev
- 1
- Next